Analyzing GRAIL (GRAL) & Its Competitors

GRAIL (NASDAQ:GRAL) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare GRAIL to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Institutional & Insider Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares GRAIL and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GRAIL	-243.80%	-16.13%	-14.38%
GRAIL Competitors	-12,323.33%	-195.38%	-30.39%

Volatility & Risk

GRAIL has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Comparatively, GRAIL’s rivals have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Valuation and Earnings

This table compares GRAIL and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GRAIL	$166.60 million	-$408.35 million	-12.32
GRAIL Competitors	$754.51 million	$13.58 million	-18.65

GRAIL’s rivals have higher revenue and earnings than GRAIL. GRAIL is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GRAIL and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1	6	5	0	2.33
GRAIL Competitors	9869	15282	45600	1598	2.54

GRAIL presently has a consensus target price of $128.80, indicating a potential upside of 10.06%. As a group, “Biotechnology” companies have a potential upside of 125.78%. Given GRAIL’s rivals stronger consensus rating and higher possible upside, analysts clearly believe GRAIL has less favorable growth aspects than its rivals.

Summary

GRAIL rivals beat GRAIL on 8 of the 13 factors compared.

GRAIL Company Profile

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.